126 related articles for article (PubMed ID: 10803936)
1. A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes.
Venditti A; Tamburini A; Buccisano F; Scimò MT; Del Poeta G; Maurillo L; Cox MC; Abruzzese E; Tribalto M; Masi M; Amadori S
Ann Hematol; 2000 Mar; 79(3):138-42. PubMed ID: 10803936
[TBL] [Abstract][Full Text] [Related]
2. Therapy of 'high risk' myelodysplastic syndromes with an association of low-dose Ara-C, retinoic acid and 1,25-dihydroxyvitamin D3.
De Rosa L; Montuoro A; De Laurenzi A
Biomed Pharmacother; 1992; 46(5-7):211-7. PubMed ID: 1467449
[TBL] [Abstract][Full Text] [Related]
3. All trans retinoic acid with low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
Nair R; Nair CN; Advani SH
Leuk Lymphoma; 1998 Mar; 29(1-2):187-92. PubMed ID: 9638988
[TBL] [Abstract][Full Text] [Related]
4. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study.
Aul C; Runde V; Gattermann N
Blood; 1993 Nov; 82(10):2967-74. PubMed ID: 8219188
[TBL] [Abstract][Full Text] [Related]
5. Low dose cytosine arabinoside in the treatment of myelodysplastic syndrome.
Nair R; Saikia TK; Gopal R; Nair CN; Soman CS; Advani SH
J Assoc Physicians India; 1996 Mar; 44(3):181-3. PubMed ID: 9251314
[TBL] [Abstract][Full Text] [Related]
6. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
8. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
[TBL] [Abstract][Full Text] [Related]
9. Combination of low-dose cytarabine and 13-cis retinoic acid in the treatment of myelodysplastic syndromes.
Ho AD; Martin H; Knauf W; Reichardt P; Trümper L; Hunstein W
Leuk Res; 1987; 11(11):1041-4. PubMed ID: 3320577
[TBL] [Abstract][Full Text] [Related]
10. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
11. Single weekly cytosine arabinoside and oral 6-thioguanine in patients with myelodysplastic syndrome and acute myeloid leukemia.
Munshi NC; Tricot GJ
Ann Hematol; 1997 Mar; 74(3):111-5. PubMed ID: 9111423
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
Hofmann WK; Ganser A; Seipelt G; Ottmann OG; Zander C; Geissler G; Hoffmann K; Höffken K; Fischer JT; Isele G; Hoelzer D
Ann Hematol; 1999 Mar; 78(3):125-30. PubMed ID: 10211754
[TBL] [Abstract][Full Text] [Related]
13. Low dose Ara-C for patients with myelodysplastic syndromes.
Powell BL; Capizzi RL; Jackson DV; Richards F; Muss HB; Lyerly ES; Rosenbaum DL; Connelly RA; Buss DH; Bearden JD
Leukemia; 1988 Mar; 2(3):153-6. PubMed ID: 3347093
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interferon alpha 2a, thymopentin and low doses of cytosine arabinoside for the treatment of myelodysplastic syndromes: a pilot study.
Venditti A; Scimò MT; del Poeta G; Buccisano F; Stasi R; Mastino A; Grelli S; Favalli C; Garaci E; Papa G
Leuk Lymphoma; 1995 Jan; 16(3-4):335-42. PubMed ID: 7719240
[TBL] [Abstract][Full Text] [Related]
17. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
Ribrag V; Suzan F; Ravoet C; Feremans W; Guerci A; Dreyfus F; Damaj G; Vantelon JM; Bourhis JH; Fenaux P
Leukemia; 2003 Feb; 17(2):319-22. PubMed ID: 12592329
[TBL] [Abstract][Full Text] [Related]
19. Combined differentiating therapy for myelodysplastic syndromes: a phase II study.
Ferrero D; Bruno B; Pregno P; Stefani S; Larizza E; Ciravegna G; Luraschi A; Vietti-Ramus G; Schinco P; Bazzan M; Gallo E; Pileri A
Leuk Res; 1996 Oct; 20(10):867-76. PubMed ID: 8960111
[TBL] [Abstract][Full Text] [Related]
20. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
